The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung ...

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously ...

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus ...

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), ...

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall ...

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, ...

A new study, published Sept. 11, 2026, in The American Journal of Human Genetics provides one possible answer: some genetic ...

A multidisciplinary scientific team at the University of Malaga has developed a new technology based on magnetic ...

Neurons receive thousands of signals via tree-like extensions called dendrites. Until now, these dendrites were thought to be ...

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the ...

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells ...

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz ...